6-(3-bromopropoxy)-3,4-dihydro-2(1H)-quinolinone | 70759-01-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 6-(3-bromopropoxy)-3,4-dihydro-2(1H)-quinolinone
• 英文别名: 6-(3-bromopropyloxy)-1,2,3,4-tetrahydro-2-quinolinone；6-(3-bromopropoxy)-3,4-dihydro-1H-quinolin-2-one
• CAS: 70759-01-2
• 化学式: C₁₂H₁₄BrNO₂
• 分子量: 284.153
• InChiKey: QGUBSLIHNLPAAL-UHFFFAOYSA-N

物化性质

• 熔点：
  112-114℃
• 密度：
  1.427

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-(3-bromopropoxy)-3,4-dihydro-2(1H)-quinolinone 生成 6-[3-[4-(2-butoxyphenyl)piperazin-1-yl]propoxy]-3,4-dihydro-1H-quinolin-2-one
  参考文献：
  名称：

  摘要：

  DOI：
• 作为产物：
  描述：

  3-氯-N-(4-甲氧基苯基)丙酰胺 在 aluminum (III) chloride 、 potassium carbonate 作用下， 以 N,N-二甲基乙酰胺 、 水 、 丙酮 为溶剂， 反应 17.0h， 生成 6-(3-bromopropoxy)-3,4-dihydro-2(1H)-quinolinone
  参考文献：
  名称：

  Pai; Samel, Asian Journal of Chemistry, 2011, vol. 23, # 4, p. 1655 - 1660

  摘要：

  DOI：

文献信息

• Cardiotonic and antithrombotic sulfur-containing derivatives of
  申请人：Boehringer Ingelheim GmbH

  公开号：US04329347A1

  公开（公告）日：1982-05-11

  Compounds of the formula ##STR1## wherein W is vinylene, methyl-vinylene, methylene or ethylene; m is 0, 1 or 2; D is straight or branched alkylene of 2 to 6 carbon atoms, straight or branched hydroxy-alkylene of 3 to 6 carbon atoms, or xylylene; R.sub.1 is hydrogen or alkyl of 1 to 3 carbon atoms; R.sub.2 is cycloalkyl of 3 to 6 carbon atoms, aryl of 6 to 10 carbon atoms, aralkyl of 7 to 11 carbon atoms, heteroaryl, heteroarlkyl, 1,2,4-triazolyl, triphenylmethyl, 4,5-bis-(p-chlorophenyl)-oxazol-2-yl, N-methyl-cyclohexylamino-carbonylmethyl,-amino-iminomethyl or, when m is 1 or D is hydroxyalkylene or xylylene, also alkyl of 1 to 6 carbon atoms; and R.sub.3 and R.sub.4 are each hydrogen, halogen, alkyl of 1 to 4 carbon atoms, amino, acetylamino or nitro. The compounds of the invention are useful as cardiotonics and as antithrombotics.

  式为##STR1##的化合物，其中W为乙烯基、甲基乙烯基、亚甲基或乙烯基；m为0、1或2；D为2至6个碳原子的直链或支链烷基、3至6个碳原子的直链或支链羟基烷基，或二甲苯基；R.sub.1为氢或1至3个碳原子的烷基；R.sub.2为3至6个碳原子的环烷基、6至10个碳原子的芳基、7至11个碳原子的芳基烷基、杂环芳基、杂环芳基烷基、1,2,4-三唑基、三苯甲基、4,5-双-(对氯苯基)-噁唑-2-基、N-甲基环己基氨基甲酰甲基、氨基亚甲基或当m为1或D为羟基烷基或二甲苯基时，也为1至6个碳原子的烷基；以及R.sub.3和R.sub.4分别为氢、卤素、1至4个碳原子的烷基、氨基、乙酰氨基或硝基。本发明的化合物可用作心力衰竭药和抗血栓药。
• Substituted phenylpiperazine derivatives
  申请人：Hoechst Aktiengesellschaft

  公开号：US04234584A1

  公开（公告）日：1980-11-18

  Phenylpiperazine derivatives of the formula I ##STR1## in which R.sup.1 denotes hydrogen or C.sub.1 -C.sub.6 alkyl, R.sup.2 denotes hydrogen or one or several, identical or different substituents selected from the group of C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 alkoxy, halogen, trifluoromethyl, hydroxy, nitro, amino and methylene-dioxy, R.sup.3 denotes hydrogen, hydroxy, C.sub.1 -C.sub.6 alkanoyloxy, and n is 1 or 2, and the physiologically acceptable salts thereof, processes for their manufacture and medicaments containing or consisting of said compounds.

  公式I的苯基哌嗪衍生物，其中R.sup.1代表氢或C.sub.1-C.sub.6烷基，R.sup.2代表氢或来自C.sub.1-C.sub.6-烷基、C.sub.1-C.sub.6烷氧基、卤素、三氟甲基、羟基、硝基、氨基和亚甲二氧基等基团中一个或几个相同或不同的取代基，R.sup.3代表氢、羟基、C.sub.1-C.sub.6烷酰氧基，n为1或2，以及其生理上可接受的盐，以及包含或由该化合物组成的制备方法和含有这些化合物的药物。
• Synthesis of 2(1H)-Quinolinone Derivatives and Their Inhibitory Activity on the Release of 12(S)-Hydroxyeicosatetraenoic Acid (12-HETE) from Platelets.
  作者：Tetsuyuki UNO、Yasushi OZEKI、Yasuo KOGA、Gil-Namg CHU、Minoru OKADA、Katsumi TAMURA、Takehiro IGAWA、Fumiko UNEMI、Masaru KIDO、Takao NISHI

  DOI：10.1248/cpb.43.1724

  日期：——

  A search for potent inhibitors of release of 12(S)-hydroxyeicosatetraenoic acid (12-HETE), which plays an important role in the pathogenesis of various circulatory disorders and arteriosclerosis, led us to 6-[4-(1-cyclohexyl-5-tetrazolyl)butoxy]-3, 4-dihydro-2(1H)-quinolinone (cilostazol) and 2(1H)-quinoinone derivatives having an azole group in the side chain. Many 2(1H)-quinolilnone derivatives were synthesized and tested in vitro for the inhibitory activity in human platelets. 3, 4-Dihydro-6-[3-(1-o-tolylimidazol-2-yl)sulfinylpropoxy]-2(1H)-quinolinone (5k) was found to be one of the most potent inhibitors of 12-HETE release, being more potent than esculetin. In addition, the sulfoxide 5k showed in vivo inhibitory activity on platelet adhesion in rats. Since 5k is recemic, the enantiomers were prepared and their potencies were compared in vitro and in vivo. (S)-(+)-5k had the best pharmacological profile and was selected as a candidate drug for further development. The structure-activity relationships are discussed.

  寻找能够有效抑制12(S)-羟基二十碳四烯酸（12-HETE）释放的化合物，这种物质在多种循环系统疾病和动脉硬化的发病机制中扮演重要角色，最终引导我们发现了6-[4-(1-环己基-5-四唑基)丁氧]-3, 4-二氢-2(1H)-喹啉酮（西洛他唑）和含有唑类侧链的2(1H)-喹啉酮衍生物。合成了多种2(1H)-喹啉酮衍生物，并在体外测试了它们对人血小板的抑制活性。3, 4-二氢-6-[3-(1-邻甲基苯基咪唑-2-基)亚砜基丙氧]-2(1H)-喹啉酮（5k）是其中一种最有效的12-HETE释放抑制剂，其效能优于依斯可林。此外，亚砜化合物5k在大鼠体内表现出对血小板粘附的抑制活性。由于5k是外消旋体，因此合成了其对映体，并比较了它们在体外和体内的效能。 (S)-(+)-5k具有最佳的药理特性，并被选为进一步开发的候选药物。文中讨论了结构-活性关系。
• Synthesis and biological evaluation of a novel sigma-1 receptor antagonist based on 3,4-dihydro-2(1H)-quinolinone scaffold as a potential analgesic
  作者：Yu Lan、Yin Chen、Xiangqing Xu、Yinli Qiu、Shicheng Liu、Xin Liu、Bi-Feng Liu、Guisen Zhang

  DOI：10.1016/j.ejmech.2014.04.019

  日期：2014.5

  antagonist activity of a new series of 3,4-dihydro-2(1H)-quinolinone derivatives are reported. The new compounds were evaluated in vitro in sigma-1 and sigma-2 receptor-binding assays in guinea pig brain membranes. The structure–activity relationship led us to the promising derivative 7-(3-(piperidin-1-yl)propoxy)-1-(4-fluorobenzyl)-3,4-dihydro-2(1H)-quinolinone (35). The compounds with highest affinity

  合成和σ-1受体（σ 1 R）拮抗剂一系列新的3,4-二氢-2（活性ħ）的报告-喹啉酮的衍生物。在豚鼠脑膜中，通过sigma-1和sigma-2受体结合测定法对新化合物进行了体外评估。构效关系使我们得到了有希望的衍生物7-（3-（哌啶-1-基）丙氧基）-1-（4-氟苄基）-3,4-二氢-2（1 H）-喹啉酮（35） 。具有最高的亲和力和选择性最高的化合物进一步成型，和化合物35具有对σ-1受体具有高结合常数（ķ我σ 1 ＝ 1.22nM）和高的sigma-1 / 2选择性（1066倍）。因此，被证明是sigma-1受体拮抗剂的化合物35成为最有趣的候选物。另外，化合物35在福尔马林试验中发挥剂量依赖性的抗伤害感受作用。这些特征表明有效和选择性的化合物35可以是用于疼痛治疗的有效候选物。
• Carbostyril derivatives and salts thereof and pharmaceutical composition
  申请人：Otsuka Pharmaceutical Co., Ltd.

  公开号：US05008274A1

  公开（公告）日：1991-04-16

  A carbostyril derivative or pharmaceutically acceptable salt thereof represented by the following general formula: ##STR1## wherein Z, A, XN, R, R.sup.1, and R.sup.2 are as defined in the specification. These carbostyril derivatives are useful in pharmaceutical compositions for inhibiting adhesion of thrombocytes.

  下列一般式所示的碳基喹啉衍生物或其制药可接受的盐：##STR1## 其中Z，A，XN，R，R.sup.1和R.sup.2如规范中所定义。这些碳基喹啉衍生物在制药组合物中用于抑制血小板粘附。